Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0FM2W
|
|||
| Former ID |
DIB012595
|
|||
| Drug Name |
Defibrotide
|
|||
| Synonyms |
Defitelio; Defibrotide (iv, veno-occlusive disease); Defibrotide (iv, veno-occlusive disease), Gentium
Click to Show/Hide
|
|||
| Indication | Hepatic veno-occlusive disease [ICD-11: DB98.6; ICD-10: K76.5] | Approved | [1] | |
| Diabetic nephropathy [ICD-11: GB61.Z; ICD-9: 250.4] | Phase 3 | [2] | ||
| Company |
Gentium
|
|||
| ADReCS Drug ID | BADD_D00598 | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76. | |||
| REF 2 | ClinicalTrials.gov (NCT00358501) Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.